文献速递肝病消化道肿瘤与早癌

非酒精性脂肪性肝炎相关肝细胞癌的分子特征

Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
PubMed 文献 · J Hepatol · 2021-05-13

该研究收集80例NASH-HCC和125例NASH样本,通过表达谱和外显子组测序比较其他病因HCC,发现NASH-HCC中ACVR2A突变率更高(10% vs 3%),并鉴定出新的突变特征MutSig-NASH-HCC,且非肝硬化患者肿瘤突变负荷更高。

要点

  • NASH-HCC常见突变基因为TERT启动子(56%)、CTNNB1(28%)、TP53(18%)和ACVR2A(10%)。
  • ACVR2A突变率在NASH-HCC中显著高于其他病因HCC(10% vs 3%,p<0.05)。
  • NASH-HCC具有独特的突变特征MutSig-NASH-HCC,且非肝硬化者突变负荷更高。

核心结论

  • NASH-HCC具有独特的分子特征,包括更高的ACVR2A突变率和新的突变特征。

研究设计与样本

  • 收集5个机构的80例NASH-HCC和125例NASH样本,进行表达谱(53例NASH-HCC,74例NASH)和外显子组测序(52例NASH-HCC),并与184例其他病因HCC比较。
  • 分析3种NASH-HCC小鼠模型(n=20)的RNA-seq/表达谱,并在HCC细胞中沉默ACVR2A评估增殖。

主要发现

  • NASH-HCC中最常见突变为TERT启动子(56%)、CTNNB1(28%)、TP53(18%)和ACVR2A(10%)。
  • ACVR2A突变率在NASH-HCC中为10%,高于其他病因HCC的3%(p<0.05)。
  • 鉴定出新的突变特征MutSig-NASH-HCC,与NASH-HCC显著相关(16% vs 病毒/酒精-HCC 2%,p=0.03)。
  • 非肝硬化NASH-HCC的肿瘤突变负荷高于肝硬化NASH-HCC(1.45 vs 0.94 mutations/megabase;p<0.0017)。
  • NASH-HCC富集胆汁和脂肪酸信号、氧化应激和炎症,Wnt/TGF-β增殖亚类比例更高(42% vs 26%,p=0.01),CTNNB1亚类比例更低,免疫抑制癌场 prevalence 更高。

关键数值与推荐

  • ACVR2A突变率:NASH-HCC 10% vs 其他病因HCC 3%(p<0.05)。
  • MutSig-NASH-HCC突变特征:NASH-HCC 16% vs 病毒/酒精-HCC 2%(p=0.03)。
  • 肿瘤突变负荷:非肝硬化NASH-HCC 1.45 mutations/megabase vs 肝硬化NASH-HCC 0.94 mutations/megabase(p<0.0017)。
  • Wnt/TGF-β增殖亚类比例:NASH-HCC 42% vs 其他病因HCC 26%(p=0.01)。

临床怎么用

  • NASH-HCC的分子特征有助于识别高风险患者及潜在靶向治疗方向。
  • ACVR2A突变和MutSig-NASH-HCC特征可作为NASH-HCC的分子标志物。
  • 非肝硬化NASH-HCC患者肿瘤突变负荷更高,可能影响免疫治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC) is increasing globally, but its molecular features are not well defined. We aimed to identify unique molecular traits characterising NASH-HCC compared to other HCC aetiologies. METHODS: We collected 80 NASH-HCC and 125 NASH samples from 5 institutions. Expression array (n = 53 NASH-HCC; n = 74 NASH) and whole exome sequencing (n = 52 NASH-HCC) data were compared to HCCs of other aetiologies (n = 184). Three NASH-HCC mouse models were analysed by RNA-seq/expression-array (n = 20). Activin A receptor type 2A (ACVR2A) was silenced in HCC cells and proliferation assessed by colorimetric and colony formation assays. RESULTS: Mutational profiling of NASH-HCC tumours revealed TERT promoter (56%), CTNNB1 (28%), TP53 (18%) and ACVR2A (10%) as the most frequently mutated genes. ACVR2A mutation rates were higher in NASH-HCC than in other HCC aetiologies (10% vs. 3%, p <0.05). In vitro, ACVR2A silencing prompted a significant increase in cell proliferation in HCC cells. We identified a novel mutational signature (MutSig-NASH-HCC) significantly associated with NASH-HCC (16% vs. 2% in viral/alcohol-HCC, p = 0.03). Tumour mutational burden was higher in non-cirrhotic than in cirrhotic NASH-HCCs (1.45 vs. 0.94 mutations/megabase; p <0.0017). Compared to other aetiologies of HCC, NASH-HCCs were enriched in bile and fatty acid signalling, oxidative stress and inflammation, and presented a higher fraction of Wnt/TGF-β proliferation subclass tumours (42% vs. 26%, p = 0.01) and a lower prevalence of the CTNNB1 subclass. Compared to other aetiologies, NASH-HCC showed a significantly higher prevalence of an immunosuppressive cancer field. In 3 murine models of NASH-HCC, key features of human NASH-HCC were preserved. CONCLUSIONS: NASH-HCCs display unique molecular features including higher rates of ACVR2A mutations and the presence of a newly identified mutational signature. LAY SUMMARY: The prevalence of hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH) is increasing globally, but its molecular traits are not well characterised. In this study, we uncovered higher rates of ACVR2A mutations (10%) - a potential tumour suppressor - and the presence of a novel mutational signature that characterises NASH-related HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Pinyol R, Torrecilla S, Wang H, et al. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2021. PMID: 33992698. doi:10.1016/j.jhep.2021.04.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。